Pascal Soriot: Thanks, Aradhana. If you look at Q3 and our operating margin and the improvement we achieved, despite what I would call a really kind of strong really 5x headwinds that really reflects the strength of the underlying business. But having said that, moving forward as Aradhana said, there’s so many variables. We need to get a better sense of where those currencies go and what the outlook for the future is, but telling the ambition remains intact at this point. The next one is Andrew at Citi. Over to you.
Andrew Baum: Yes, thank you. A couple of questions. Firstly, could you talk to the outlook for your COVID-19 monoclonal antibodies Evusheld? On the one hand, you’ve got escape variants, which may impact the EUA. On the other hand, I know you have next generation monoclonal, so if you could update us on timing and how you’re thinking about what you intend to deliver to the market next year, that’d be helpful. And then second, Farxiga obviously is a cornerstone diabetes drug. But the road is running out although you do have lifecycle management strategies. I know you have a long standing collaboration with Amgen, which doesn’t have a primary care business. They recently posted data with AMG133. You killed your glue agent in diabetes and in obesity.
I’m just curious as whether there will be any appetite for engaging in extending that collaboration. Any thoughts there. And then finally, very quickly, feel free to pass on this. Can you tell me why shouldn’t expect Calquence to be significantly revised downwards given near-term the NCCN guidelines and the second Imbruvica, they will have a price negotiation cutter about 65% to 26. Feel free to pass on those in the interest of time.
Pascal Soriot: Thank you, Andrew, and I’m so happy that Andy took the thankless task of asking everybody one question. He has not succeeded at all so far today. Can we quickly cover the last one Dave or you want to start with this one and Iskra could cover the monoclonal and Evusheld.
David Fredrickson: So, Andrew, from our perspective, as we continue to look at the performance of Calquence, we see that really the results, whether it’s from our own ELEVATE-TN studies, the ALPINE results, what we’re seeing coming out at ASH, that all of this underscores our belief and I think it’s consistent with what we hear from the marketplace that the next generation BTKi like Calquence have a differentiated and better profile than the first generation BTKi. And I think that this is what gives us confidence in our ability to continue to establish Calquence as the standard of care within this next generation class. When I take a look at the progress that other competitors have made in places where we face head-to-head competition in the U.S and MCL in the relapsed refractory setting, Calquence share has held strong.
The gains that have made have come at the expense of . And we continue to see good progress being made in terms of innovations with things like the maleate tablet formation.
Pascal Soriot: Thank you, Dave.
Iskra Reic: Thanks, Andrew, for the question. Let me first address your first part of your question around the Evusheld outlook. So I think it’s important to know that Evusheld is still playing a very important role for the immunocompromised patient. As we know, this is the only option for those patients to be protected from COVID-19. And we also know that they are under significant higher risk of the hospitalization and that from COVID. Now, it is true that the new variants that we see arising can have a — can cause the decrease of the — activity of Evusheld. And we obviously together with the government’s monitoring and collecting the data, both in vitro lab neutralizing data as well as real world effectiveness data to make sure that Evusheld keeps clinical efficacy for those patients.
